Rate My Professor Danny Huang

Professor Danny Huang holds the position of Professor of Cancer Structural Biology at the CRUK Scotland Institute, affiliated with the University of Glasgow's School of Cancer Sciences. He obtained his Bachelor of Science in Biochemistry with First Class Honours in 1996 and his PhD in 2002 from the University of Sydney under the supervision of Richard Christopherson. Huang commenced his postdoctoral training in 2002 with Brenda Schulman at St Jude Children’s Research Hospital, continuing there until 2005, followed by a fellowship at HHMI in 2006-2007, and serving as Staff Scientist from 2007 to 2009. Since 2009, he has been Group Leader of the Ubiquitin Signalling group at the CRUK Scotland Institute.

Huang's research investigates the ubiquitin-proteasome system, focusing on post-translational modifications by ubiquitin and ubiquitin-like proteins that govern critical cellular functions such as cell cycle progression, transcription, DNA repair, and virus budding. Dysregulation of these pathways contributes to cancer, neurodegenerative diseases, and viral infections. His laboratory employs X-ray crystallography and biochemical techniques to dissect the regulatory mechanisms and catalytic functions of RING E3 ubiquitin ligases, comprising approximately 600 members in humans. Notable achievements include elucidating the basis for a ubiquitin-like protein thioester switch (Nature, 2007), E2-RING expansion in the NEDD8 cascade (Molecular Cell, 2009), structural basis for c-Cbl autoinhibition and activation (Nature Structural & Molecular Biology, 2012), mechanism of ubiquitin transfer by BIRC7 RING dimer (Nature Structural & Molecular Biology, 2012), activation by non-covalent ubiquitin (Molecular Cell, 2015), and separating MDM2 degradation from p53 regulation (Nature Structural & Molecular Biology, 2017). Recent publications address tuning ubiquitin transfer by RING E3s (Life Science Alliance, 2025), DTX3L ubiquitination of single-stranded nucleic acids (eLife, 2024), and engineered ubiquitin binding peptides (Chemical Science, 2024). In 2006, he was awarded the Lorne Protein Young Investigator Award. His structural studies have paved the way for E1 inhibitors now in clinical trials and novel PROTAC-based therapies, demonstrating reduced toxicity in MDM2-p53 targeting.